Vaccine Therapy for Patients With Stage III Melanoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2004 by CancerVax Corporation.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
CancerVax Corporation
ClinicalTrials.gov Identifier:
NCT00052130
First received: January 22, 2003
Last updated: June 23, 2005
Last verified: September 2004

January 22, 2003
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00052130 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Vaccine Therapy for Patients With Stage III Melanoma
Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma

This is a Phase 3 study in patients with melanoma that has spread to the lymph nodes (stage III), and who have had all of their cancer surgically removed. The purpose of this study is to evaluate the ability of the CancerVax™ vaccine to prevent or slow the recurrence of melanoma.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Malignant Melanoma
Biological: CancerVax vaccine (CANVAXIN)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
1118
Not Provided
Not Provided
  • Must have Stage III melanoma
  • Must have had all clinically-detectable disease surgically removed
  • Cannot be taking any medications, or undergoing any therapies which compromise the functioning of your immune system (ie. Some corticosteroids, and certain types of radiation therapy)
  • Cannot have HIV or Hepatitis A, B, or C
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
United States,   Australia,   Brazil,   Canada,   France,   Germany,   Ireland,   Israel,   Italy,   Netherlands,   New Zealand,   Switzerland,   United Kingdom
 
NCT00052130
CV-MMAIT-3-001, JWCI-MC-3-001A
Not Provided
Not Provided
CancerVax Corporation
Not Provided
Not Provided
CancerVax Corporation
September 2004

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP